Specialist Updates 
Cardiology

Dapagliflozin improves CKD outcomes ‘even without diabetes’

The drug has potential for people with renal disease in need of improved treatment options, investigators say
Medicom Staff writer
0
3 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Use of dapagliflozin in patients with chronic kidney disease can improve outcomes in patients with and without type 2 diabetes, trial results show.

Results of the DAPA-CKD trial were presented to delegates at the European Society of Cardiology’s virtual congress (ESC 2020) this week.

More than 4300 participants were enrolled in the international trial, all with chronic kidney disease (CKD), having an estimated glomerular filtration rate (eGFR) of between 25-75mL/min/1.74m2 and a urinary albumin to creatinine ratio of more than 200mg/g.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .